How have IHE shares performed in 2023?

iShares U.S. Pharmaceuticals ETF's stock was trading at $186.13 on January 1st, 2023. Since then, IHE stock has decreased by 4.2% and is now trading at $178.3259. View the best growth stocks for 2023 here .

What does IHE invest in?

iShares U.S. Pharmaceuticals ETF is a equity fund issued by iShares. IHE focuses on health care investments and follows the Dow Jones U.S. Select Pharmaceuticals Index. The fund's investments total to approximately $588.21 million assets under management.

What stocks does iShares U.S. Pharmaceuticals ETF hold?

IHE invests in 38 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY) , Johnson & Johnson (JNJ) , Zoetis (ZTS) , Viatris (VTRS) , Merck & Co., Inc. (MRK) , Bristol-Myers Squibb (BMY) , Pfizer (PFE) , Royalty Pharma (RPRX) , Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT) .

What is the management fee for iShares U.S. Pharmaceuticals ETF?

iShares U.S. Pharmaceuticals ETF's management fee is 0.39% and has no other recorded expenses or fee waivers. The net expense ratio for IHE is 0.39%.

What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares U.S. Pharmaceuticals ETF investors own include United Parcel Service (UPS) , CVS Health (CVS) , Genuine Parts (GPC) , Intel (INTC) , Kinder Morgan (KMI) , Wells Fargo & Company (WFC) , Archer-Daniels-Midland (ADM) , BP (BP) and Campbell Soup (CPB) .

Who are iShares U.S. Pharmaceuticals ETF's major shareholders?

iShares U.S. Pharmaceuticals ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (3.12%), Raymond James & Associates (2.78%), Royal Bank of Canada (1.81%), RiverFront Investment Group LLC (1.76%), LPL Financial LLC (1.18%) and UBS Group AG (0.72%).

How do I buy shares of iShares U.S. Pharmaceuticals ETF?

Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News

$178.33

+0.69 (+0.39%)

(As of 12/8/2023 ET)

Compare

Today's Range: $177.13
▼
$178.50
50-Day Range: $166.63
▼
$181.97
52-Week Range: $166.09
▼
$191.74

Volume: 18,429 shs
Average Volume: 14,161 shs
Market Capitalization: $365.57 million

Assets Under Management: $588.21 million
Dividend Yield: 2.09%
Net Expense Ratio: 0.39%

Stock Analysis Chart Headlines Holdings Ownership Ratings

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors.

IHE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IHE ETF News Headlines

November 17, 2023 | seekingalpha.com

IHE iShares U.S. Pharmaceuticals ETF

November 15, 2023 | lse.co.uk

Ishares Uk Property Ucits Etf Gbp Dist Share Price (IUKP.MI)

December 9, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 12, 2023 | lse.co.uk

Ishares $ Ultrashort Bond Ucits Etf Share Price (ERND.AM)

October 19, 2023 | msn.com

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

October 18, 2023 | finance.yahoo.com

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

August 21, 2023 | msn.com

IHE: A Highly Concentrated Portfolio Is Able To Generate Growth Over The Long Run

August 15, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights URNJ, IHE and PXE

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 15, 2023 | msn.com

Pharma ETF (IHE) Hit a 52-Week High

See More Headlines

Receive IHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: iShares
Fund Name: iShares U.S. Pharmaceuticals ETF
Tax Classification: Regulated Investment Company
Stock Exchange: NYSEARCA
Current Symbol: NYSEARCA:IHE
Inception Date: 5/1/2006
Fund Manager: Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Web: www.iShares.com
Phone: N/A

Fund Focus

Asset Class: Equity
Benchmark: Dow Jones U.S. Select Pharmaceuticals Index
Category: Sector
Focus: Health Care
Development Level: Developed Markets
Region: North America
Number of Holdings: 38

Fund Statistics

Assets Under Management: $588.21 million
Average Daily Volume: $14,094.10
Discount/Premium: 0.08%

Administrator, Advisor and Custodian

Administrator: Citibank, N.A.
Advisor: BlackRock Fund Advisors
Custodian: Citibank, N.A.
Distributor: BlackRock Investments, LLC
Transfer Agent: Citibank, N.A.
Trustee: N/A
Lead Market Maker: Latour Trading

Options

Optionable: N/A
Short Interest: 33,700 shs

Miscellaneous

Outstanding Shares: 2,050,000
Beta: 0.70
Creation Unit: 50,000
Creation Fee: $306.00

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

iShares U.S. Pharmaceuticals ETF Expenses

Type	IHE	Health Care ETFs	Equity ETFs	NYSEARCA ETFs	All ETFs
Management Fee	0.39%	0.56%	0.53%	0.50%	0.51%
Other Expenses	0.00%	0.40%	0.54%	0.64%	0.57%
Total Expense	0.39%	0.72%	0.70%	0.73%	0.70%
Fee Waiver	0.00%	-0.51%	-0.54%	-0.69%	-0.57%
Net Expense	0.39%	0.61%	0.60%	0.57%	0.57%

iShares U.S. Pharmaceuticals ETF (IHE) Holdings & Exposure

Top 10 IHE Holdings

IHE Sector Exposure

IHE Industry Exposure

Full Holdings Details

Key Executives

George G. C. Parker Ph.D. (Age 78)
Independent Chairman of the Board of Trustees
Michael Arthur Latham (Age 51)
President, Trustee
Jack Gee (Age 57)
Chief Financial Officer, Treasurer
Geoffrey D. Flynn
Chief Operating Officer, Executive Vice President
Amy Schioldager (Age 56)
Executive Vice President
Ira P. Shapiro (Age 52)
Vice President, Chief Legal Officer
Matt Tucker
Vice President
Eilleen M. Clavere (Age 61)
Secretary
Cecilia H. Herbert (Age 68)
Independent Trustee
Charles A. Hurty (Age 73)
Independent Trustee

Similar ETFs

Institutional Ownership

View All Institutional Transactions

IHE ETF - Frequently Asked Questions

How have IHE shares performed in 2023?: iShares U.S. Pharmaceuticals ETF's stock was trading at $186.13 on January 1st, 2023. Since then, IHE stock has decreased by 4.2% and is now trading at $178.3259.
View the best growth stocks for 2023 here.
What does IHE invest in?: iShares U.S. Pharmaceuticals ETF is a equity fund issued by iShares. IHE focuses on health care investments and follows the Dow Jones U.S. Select Pharmaceuticals Index. The fund's investments total to approximately $588.21 million assets under management.
What stocks does iShares U.S. Pharmaceuticals ETF hold?: IHE invests in 38 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Zoetis (ZTS), Viatris (VTRS), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Pfizer (PFE), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT).
What is the management fee for iShares U.S. Pharmaceuticals ETF?: iShares U.S. Pharmaceuticals ETF's management fee is 0.39% and has no other recorded expenses or fee waivers. The net expense ratio for IHE is 0.39%.

What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other iShares U.S. Pharmaceuticals ETF investors own include United Parcel Service (UPS), CVS Health (CVS), Genuine Parts (GPC), Intel (INTC), Kinder Morgan (KMI), Wells Fargo & Company (WFC), Archer-Daniels-Midland (ADM), BP (BP) and Campbell Soup (CPB).
Who are iShares U.S. Pharmaceuticals ETF's major shareholders?: iShares U.S. Pharmaceuticals ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (3.12%), Raymond James & Associates (2.78%), Royal Bank of Canada (1.81%), RiverFront Investment Group LLC (1.76%), LPL Financial LLC (1.18%) and UBS Group AG (0.72%).
How do I buy shares of iShares U.S. Pharmaceuticals ETF?: Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEARCA:IHE) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial